Bronchopulmonary Dysplasia Pipeline Review 2020: Therapeutic Analysis of 16 Companies & 8 Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bronchopulmonary Dysplasia – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Bronchopulmonary Dysplasia – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews the key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. (Read more…)
• The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Key Topics Covered:

Introduction

Report Coverage

• Bronchopulmonary Dysplasia – Overview
• Bronchopulmonary Dysplasia – Therapeutics Development

Pipeline Overview

• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes

Bronchopulmonary Dysplasia – Therapeutics Assessment

• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Bronchopulmonary Dysplasia – Companies Involved in Therapeutics Development

• Advent Therapeutics Inc
• Airway Therapeutics LLC
• Ayuvis Research Inc
• Chiesi Farmaceutici SpA
• Insmed Inc
• Laboratoire Aguettant SA
• MediPost Co Ltd
• Meridigen Biotech Co Ltd
• Orphanix GmbH
• Radikal Therapeutics Inc
• Syntrix Biosystems Inc
• Takeda Pharmaceutical Co Ltd
• The Cell Factory BVBA
• Trimunocor Ltd
• United Therapeutics Corp
• Windtree Therapeutics Inc

Bronchopulmonary Dysplasia – Drug Profiles

• Aerosurf
• AT-100
• AVR-48
• CFMEV-132
• Drugs for Bronchopulmonary Dysplasia
• hydrocortisone hemisuccinate
• mecasermin rinfabate
• Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia

Bronchopulmonary Dysplasia – Dormant Projects

• Bronchopulmonary Dysplasia – Discontinued Products
• Bronchopulmonary Dysplasia – Product Development Milestones

Featured News & Press Releases

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xj961n

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900